FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy By Ogkologos - July 1, 2026 152 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CADENZA study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR 4 Ways to Avoid Comparing Yourself to Others on Social Media... October 31, 2023 Off Target: Investigating the Abscopal Effect as a Treatment for Cancer January 28, 2020 ESMO awards its first fellowship to support digital and computational pathology September 10, 2025 Girl Scout’s Pink Chair Project Loans Recliners to Women Recovering from... December 21, 2021 Load more HOT NEWS Coping With the Holidays During COVID-19 and Cancer FDA Approves Elacestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... Lisocabtagene Maraleucel in Relapsed or Refractory Large B-cell Lymphomas Proof of Concept for the Safety and Immunogenicity of Lymph Node...
